Investors & Media
Corporate Profile
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases.
Stock Quote
- Change
- Volume
- Today's Open
- Previous Close
- Today's High
- Today's Low
- 52 Week High
- 52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Contacts
Investor Contact
Meredith Kaya
(617) 599-8178
meredith.kaya@apellis.com
Media Relations
Lissa Pavluk
(617) 977-6764
media@apellis.com